Literature DB >> 343727

Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.

F Van Gerwen, J K Van der Korst, F W Gribnau.   

Abstract

In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 343727      PMCID： PMC1000198          DOI： 10.1136/ard.37.1.85

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  8 in total

1.  Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.

Authors:  H F Hill; A G Hill; A G Mowat; B M Ansell; J A Mathews; M H Seifert; J M Gumpel; G A Christie
Journal:  Ann Rheum Dis       Date:  1974-01       Impact factor: 19.103

2.  Assessment of the flexibility of the lumbar spine. A pilot study in children and adolescents.

Authors:  J A van Adrichem; J K van der Korst
Journal:  Scand J Rheumatol       Date:  1973       Impact factor: 3.641

3.  Ankylosing spondylitis: open long-term and double-blind crossover studies with naproxen.

Authors:  H F Hill; A G Hill
Journal:  J Clin Pharmacol       Date:  1975-04       Impact factor: 3.126

4.  [A double blind comparison of naproxen and indomethacin on the after-midnight-pain of patients with morbus bechterew].

Authors:  E Peter
Journal:  Arzneimittelforschung       Date:  1975-02

5.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.

Authors:  J W Boersma
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

6.  Four new anti-inflammatory drugs: responses and variations.

Authors:  E C Huskisson; D L Woolf; H W Balme; J Scott; S Franklin
Journal:  Br Med J       Date:  1976-05-01

7.  Naproxen metabolism in man.

Authors:  E J Segre
Journal:  J Clin Pharmacol       Date:  1975-04       Impact factor: 3.126

8.  Anti-inflammatory and analgetic properties of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen).

Authors:  A P Roszkowski; W H Rooks; A J Tomolonis; L M Miller
Journal:  J Pharmacol Exp Ther       Date:  1971-10       Impact factor: 4.030
  8 in total
  7 in total

1.  Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

Authors:  Caroline T Nguyen; Michael I MacEntee; Barbara Mintzes; Thomas L Perry
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 2.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 3.  Ankylosing spondylitis: an overview.

Authors:  J Sieper; J Braun; M Rudwaleit; A Boonen; A Zink
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 4.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

5.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 6.  Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-10       Impact factor: 9.546

Review 7.  Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Authors:  Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde
Journal:  Cochrane Database Syst Rev       Date:  2015-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.